Initial trials suggested that pretreatment tumor PD‐L1 expression was correlated with response to anti‐PD‐1/PD‐L1 therapies in RCC, yet, a majority of patients with PD‐L1(+) tumors did not respond to the treatment and a considerable number of patients classified as PD‐L1‐negative still benefit from the treatment.[64] Therefore, many observations have questioned the prospect of using PD‐L1 expression for predicting therapeutic activity of PD‐1/PD‐L1 blockade. Here, CD274 is linked to renal cell carcinoma.